Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
rezetamig (JNJ-8780)
i
Other names:
JNJ-8780, JNJ-75348780
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
J&J
Drug class:
CD3 agonist, CD22 inhibitor
Related drugs:
‹
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
BL-22 (0)
Imtox19/Imtox22 (0)
epratuzumab (0)
IgG-RFB4-SMPT-dgA (0)
epratuzumab Y-90 (0)
REGN5837 (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
TAC-001 (0)
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IBI-389 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
BL-22 (0)
Imtox19/Imtox22 (0)
epratuzumab (0)
IgG-RFB4-SMPT-dgA (0)
epratuzumab Y-90 (0)
REGN5837 (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
TAC-001 (0)
›
Associations
News
Trials
Filter by
Latest
27d
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
P1, N=40, Recruiting, Janssen Research & Development, LLC
27 days ago
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
11ms
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2026 --> May 2025
11 months ago
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
11ms
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
11 months ago
Enrollment open • Trial completion date • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
12ms
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2023 --> Apr 2025
12 months ago
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
1year
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
P1, N=70, Not yet recruiting, Janssen Research & Development, LLC
1 year ago
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
1 year ago
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
over1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2023 --> Oct 2023
over 1 year ago
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
over1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2025 --> Sep 2026
over 1 year ago
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost2years
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=200, Recruiting, Janssen Research & Development, LLC | N=120 --> 200
almost 2 years ago
Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost2years
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2024 --> May 2025
almost 2 years ago
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost3years
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2023 --> Sep 2023
almost 3 years ago
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login